Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Nutr Sci ; 10: e73, 2021.
Article in English | MEDLINE | ID: mdl-34589205

ABSTRACT

Montmorency tart cherries (MC) have been found to modulate indices of vascular function with interventions of varying duration. The objective of this preliminary study was to identify the chronic effects of MC supplementation on vascular function and the potential for urinary metabolomics to provide mechanistic evidence. We performed a placebo-controlled, double-blind, randomised study on 23 healthy individuals (18M, 7F) that consumed 30 ml MC or a placebo twice daily for 28 days. Whole body measures of vascular function and spot urine collections were taken at baseline and after supplementation. There were no significant changes to vascular function including blood pressure and arterial stiffness. Urinary metabolite profiling highlighted significant changes (P < 0⋅001) with putative discriminatory metabolites related to tryptophan and histidine metabolism. Overall, MC supplementation for 28 days does not improve indices of vascular function but changes to the urinary metabolome could be suggestive of potential mechanisms.


Subject(s)
Cardiovascular System , Fruit , Prunus avium , Urine/chemistry , Blood Pressure , Dietary Supplements , Female , Humans , Male , Metabolome , Pilot Projects , Vascular Stiffness
2.
BMJ Open ; 6(4): e009537, 2016 Apr 29.
Article in English | MEDLINE | ID: mdl-27130160

ABSTRACT

BACKGROUND: X linked intellectual disability (XLID) syndromes account for a substantial number of males with ID. Much progress has been made in identifying the genetic cause in many of the syndromes described 20-40 years ago. Next generation sequencing (NGS) has contributed to the rapid discovery of XLID genes and identifying novel mutations in known XLID genes for many of these syndromes. METHODS: 2 NGS approaches were employed to identify mutations in X linked genes in families with XLID disorders. 1 involved exome sequencing of genes on the X chromosome using the Agilent SureSelect Human X Chromosome Kit. The second approach was to conduct targeted NGS sequencing of 90 known XLID genes. RESULTS: We identified the same mutation, a c.12928 G>C transversion in the HUWE1 gene, which gives rise to a p.G4310R missense mutation in 2 XLID disorders: Juberg-Marsidi syndrome (JMS) and Brooks syndrome. Although the original families with these disorders were considered separate entities, they indeed overlap clinically. A third family was also found to have a novel HUWE1 mutation. CONCLUSIONS: As we identified a HUWE1 mutation in an affected male from the original family reported by Juberg and Marsidi, it is evident the syndrome does not result from a mutation in ATRX as reported in the literature. Additionally, our data indicate that JMS and Brooks syndromes are allelic having the same HUWE1 mutation.


Subject(s)
Chromosomes, Human, X/genetics , Deafness/genetics , Growth Disorders/genetics , Hypogonadism/genetics , Mental Retardation, X-Linked/genetics , Muscle Spasticity/genetics , Ubiquitin-Protein Ligases/genetics , Adolescent , Adult , Child , Exome , Facies , Genetic Diseases, X-Linked , High-Throughput Nucleotide Sequencing , Humans , Intellectual Disability , Male , Megalencephaly , Middle Aged , Mutation , Tumor Suppressor Proteins , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...